PTC Therapeutics Q4 Earnings Call Highlights

Core Insights - PTC Therapeutics reported significant growth in revenue driven by the launch of Sephience for phenylketonuria (PKU), achieving $92 million in the fourth quarter and $111 million since its launch in 2025 [1][4][7] - The company exceeded its revenue guidance for 2025, reporting total net product and royalty revenue of $831 million, up from the previous guidance of $750 million to $800 million [2][6] Financial Performance - For Q4 2025, PTC's total net product and royalty revenue was $263 million, contributing to a full-year total of $831 million [2][4] - The company ended 2025 with $1.95 billion in cash, following the monetization of Evrysdi royalties for $240 million upfront [6][22][23] - PTC guided for 2026 product revenue between $700 million and $800 million, indicating a growth of 19% to 36% compared to 2025 [24] Product Development and Approvals - Sephience received approvals in the U.S., E.U., and Japan, with early commercial momentum noted through broad uptake across various patient demographics [3][7][8] - The company plans to expand Sephience's commercial footprint internationally, targeting 20 to 30 countries by the end of 2026 [11][13] Market Dynamics - Payers have shown favorable early reimbursement for Sephience, with minimal barriers to access and long refill periods [9][10] - The company is addressing the needs of "lost to follow-up" adults, leveraging social media and community networks to re-engage patients [10] Pipeline Updates - PTC is advancing its pipeline with Votoplam for Huntington's disease, with a phase III trial expected to start in H1 2026 [5][18] - For Vatiquinone, an additional study is required for NDA resubmission, with plans to align on the protocol with the FDA [19] Other Revenue Streams - The Duchenne muscular dystrophy (DMD) franchise contributed $66 million in Q4, with Evrysdi royalties generating $79 million [14][15] - The company continues to face challenges in the DMD market due to increased generic competition [15]